ChiCTR1900023627 版本V1.0 版本创建时间2021/01/11 22:18:06 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900023627 

最近更新日期:

Date of Last Refreshed on:

2019-06-04 20:57:31 

注册时间:

Date of Registration:

2019-06-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同剂量顺式阿曲库铵对甲状腺手术神经监测的影响

Public title:

Effects of different doses of cisatracurium on nerve monitoring in thyroid surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同剂量的顺式阿曲库铵在甲状腺手术中对 喉返神经监测的影响

Scientific title:

Effects of different doses of cisatracurium on intraoperative laryngeal nerve monitoring in patients with thyroid surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙晓茹 

研究负责人:

李成 

Applicant:

Xiaoru Sun 

Study leader:

Cheng Li 

申请注册联系人电话:

Applicant telephone:

+86 15950576393

研究负责人电话:

Study leader's telephone:

+86 15121081239

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sunxiaorusara@163.com

研究负责人电子邮件:

Study leader's E-mail:

marklisa@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市静安区延长中路301号

研究负责人通讯地址:

上海市静安区延长中路301号

Applicant address:

301 Middle Yanchang Road, Jing'an District, Shanghai, China

Study leader's address:

301 Middle Yanchang Road, Jing'an District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第十人民医院

Applicant's institution:

Shanghai Tenth People's Hospital

研究负责人所在单位:

上海市第十人民医院

Affiliation of the Leader:

Shanghai Tenth People's Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第十人民医院

Primary sponsor:

Shanghai Tenth People's Hospital

研究实施负责(组长)单位地址:

上海市静安区延长中路301号

Primary sponsor's address:

301 Middle Yanchang Road, Jing'an District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第十人民医院

具体地址:

上海市静安区延长中路301号

Institution
hospital:

Shanghai Tenth People's Hospital

Address:

301 Middle Yanchang Road, Jing'an District, Shanghai, China

经费或物资来源:

自筹经费

Source(s) of funding:

Self-financing

Target disease:

Thyroid disease

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

不同剂量对照 

Study design:

Dose comparison 

研究目的:

本研究旨在通过应用不同诱导剂量的顺式阿曲库铵,探索既满足麻醉插管及术中管理需求,又满足外科医生术中神经监测的最佳剂量。  

Objectives of Study:

The aim of this study was to explore the optimal dose for both anesthesia intubation and intraoperative management, as well as to meet the surgeon's intraoperative neurological monitoring by applying different doses of cis-atracurium.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、患者大于18周岁,小于65周岁,ASA 分级I-II级。
2、患者被诊断出甲状腺疾病,需行甲状腺手术。
3、患者能够理解并自愿签署知情同意书。
4、患者愿意遵循研究要求,配合研究者访视时间。

Inclusion criteria

1. Aged 18 to 65 years old, and the ASA I-II;
2. patient with thyroid disease, requiring thyroid surgery;
3. Be able to understand and voluntarily sign the informed consent form;
4. Be able to follow the research requirements and cooperate with the researcher's visit time.

排除标准:

1、术前存在声音嘶哑患者
2、恶性肿瘤,严重心脑血管疾病、全身情况差患者。
3、合并神经及内分泌系统疾病患者
4、小下颌或面部有畸形及有困难气道病史的患者。
5、有活动性感染。
6、有药物滥用史。
7、交流有障碍,无法正常客观描述症状。
8、当前正在参与另一项临床研究。
9、当前正在使用任何实验药物(未经卫生机构批准的产品)。

Exclusion criteria:

1. hoarseness before surgery;
2. malignant tumors, severe cardiovascular and cerebrovascular diseases, poor general condition;
3. Patients with neurological and endocrine diseases;
4. Patients with small mandibular or facial deformities and a history of difficult airway disease;
5. With active infections;
6. With a history of drug abuse;
7. Difficult on communication, unable to describe who's own symptoms;
8. Currently participating in another clinical study;
9. Any experimental drug (product not approved by a health agency) is currently in use.

研究实施时间:

Study execute time:

From 2019-06-01 00:00:00 To 2019-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-06-30 00:00:00 To 2019-12-31 00:00:00  

干预措施:

Interventions:

组别:

3组

样本量:

120

Group:

Three Groups

Sample size:

干预措施:

不同剂量的顺式阿曲库铵

干预措施代码:

Intervention:

different doses of cis-atracurium.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市第十人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Tenth People's Hospital

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

气管插管条件评分

指标类型:

主要指标

Outcome:

Tracheal intubation condition score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

实验人员按照随机数字表法随机分为3组

Randomization Procedure (please state who generates the random number sequence and by what method):

The experimenters were randomly divided into 3 groups according to the random number table method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用临床试验公共管理平台并向公众开放查询

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Adopt a clinical trial public management platform and open queries to the public

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用临床试验公共管理平台管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Management using a clinical trial public management platform

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-06-04 20:57:31